Submissions and Approvals

Experts Unsure on Breakthrough Therapy Designation’s Potential

The FDA’s breakthrough therapy program is proving its potential to advance new drugs and biologics targeting unmet needs, a new Tufts University report says. But industry interest in the year-old program may wane if the approval times for breakthrough drugs don’t improve. Read More